Document Detail

Poly(ADP-ribosylation) and neoplastic transformation:Effect of PARP inhibitors.
MedLine Citation:
PMID:  22429135     Owner:  NLM     Status:  Publisher    
Poly(ADP-ribose) polymerases (PARPs) and poly(ADP-ribosylation) play essential roles in several biological processes, among which neoplastic transformation and telomere maintenance. In this paper, we review the poly(ADP-ribosylation) process together with the highly appealing use of PARP inhibitors for the treatment of cancer. In addition, we report our results concerning poly(ADP-ribosylation) in a cellular model system for neoplastic transformation developed in our laboratory. Here we show that PARP-1 and PARP-2 expression increases during neoplastic transformation, together with the basal levels of poly(ADP-ribosylation). Furthermore, we demonstrate a greater effect of the PARP inhibitor 3-aminobenzamide (3AB) on cellular viability in neoplastically transformed cells compared to normal fibroblasts and we show that prolonged 3AB administration to tumorigenic cells causes a decrease in telomere length. Taken together, our data support an active involvement of poly(ADP-ribosylation) in neoplastic transformation and telomere length maintenance and confirm the relevant role of poly(ADP-ribosylation) inhibition for the treatment of cancer.
Francesca Donà; Ilaria Chiodi; Cristina Belgiovine; Tatiana Raineri; Roberta Ricotti; Chiara Mondello; A Ivana Scovassi
Related Documents :
5638885 - The centriole cycle in synchronized hela cells.
10954605 - The majority of human replication protein a remains complexed throughout the cell cycle.
20002525 - Dna methylation regulates adenosine a(2a) receptor cell surface expression levels.
6700585 - Factors influencing the accumulation of tetraphenylphosphonium cation in hela cells.
25118935 - Impaired cell death and mammary gland involution in the absence of dock1 and rac1 signa...
25345415 - Besides neuro-imaging, the thy1-yfp mouse could serve for visualizing experimental tumo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-20
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  -     ISSN:  1873-4316     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Istituto di Genetica Molecolare CNR, Via Abbiategrasso 207, 27100 Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Capsid Assembly as a Point of Intervention for Novel Anti-viral Therapeutics.
Next Document:  X-ray Crystallography as a tool for Mechanism-of-action Studies and Drug Discovery.